Hemmie Chang is a Partner at Foley Hoag LLP, where she chairs the Licensing & Strategic Alliances Practice Group and focuses on complex collaboration and licensing transactions. She is a member of the firm's Life Sciences, Venture Capital & Emerging Companies, and Energy Technology & Renewables practices. Hemmie has over two decades of experience advising both pharmaceutical and emerging biotech companies on IP transactions, including the acquisition and disposition of assets. Representative Experience The following is a brief summary of Hemmie's experience and accomplishments: · Collaboration and licensing transactions, mergers and acquisitions and investments for major pharmaceutical and emerging high-growth companies, including:
- Research and development deal with equity co-investment and option to purchase with a major device manufacturer.
- Metamark Genetics-Janssen Biotech early stage discovery collaboration deal in cancer (up to $365 million).
- Early stage discovery and equity investment deal with a major European partner.
- Development and supply agreement for the U.S. subsidiary of a major Japanese conglomerate.
- Represented Arisaph Pharmaceuticals in a major reset of royalty and other payments to monetize $26.25 million in upfront and ongoing payments from Royalty Pharma.
- Translational Therapeutics Inc.-Clavis Pharma, Inc. oncology candidate in-license (BioWorld International Deal of the Week).
- Negotiation of licenses for nanotechnology companies.
- Advise on genomic sequencing licensing matters.
- Spinoff of assets (e.g. oncology programs, deep brain stimulation technology).
- Advise on numerous academic licenses from Harvard, MIT, Whitehead Institute, Johns Hopkins and UCSF.
- Representation of lead investor in an over $1 billion investment in the largest contract research organization worldwide.
- Acquisition of pediatric asset and related collaboration.
- Representation of a bidder for a Fortune 100 company's sale of its imaging business. · Investments, mergers and acquisitions and financings in energy and renewables (solar, wind) and other projects. Professional / Civic Involvement · South Cove Manor, Nursing & Rehabilitation Center, Inc. and South Cove Nursing Facilities Foundation, Board Member · Franklin Square House Foundation, Board Member · National Asian Pacific American Bar Association (NAPABA), Member · The Commonwealth of Massachusetts Advisory Group on Undergraduate Education, Member · Asian American Lawyers Association of Massachusetts, Founding Director · Asian Task Force Against Domestic Violence, Founding Director Speeches and Conferences · Mergers and Acquisitions/IP Law Panel, American Intellectual Property Law Association (AIPLA) Annual Conference (October 2011) · "Partnering a Platform Technology Today When Companies Want a Drug Tomorrow," BioNetwork West (October 2011) · "Corporate Partnering Health Care/Life Sciences," MassChallenge Panel (August 2011) · "State of Licensing 2011 Update," Biotechnology Industry Organization (BIO) 2011 Webinar (May 2011) · "Starting a Business in China: Legal Considerations," MIT Sloan 2010 Asia Business Conference (November 2010) · "Current Trends of Global M&A," Private Equity Korea - Global Bio & Medical Forum 2010 (June 2010) · "How to Acquire New Products and Technologies: What's New/What's Not," Biotechnology International Convention (May 2010) Publications · Author, 2010 supplement to Chapter 15: "Foreign Corporations," Massachusetts Corporation Law and Practice (by R. Southgate and D. Glazer), National Corporation Law Series. Industries Life Sciences Venture Capital & Emerging Companies Honors/Awards Articles Editor, Harvard Law Review Phi Beta Kappa, Woodrow Wilson School of Public and International Affairs Related Professional Experience Biotechnology Industry Organization, Moderator and Speaker Massachusetts Biotechnology Council, Faculty Massachusetts Continuing Legal Education, Faculty |